Erytech Pharma
0
0
+€0.00+0% 00:00 Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Financials
-Profit Margin
Unprofitable0Revenue
-23.49MNet Income
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
PHAXIAM Therapeutics S.A., a clinical-stage biopharmaceutical company, focuses on developing bacteriophage-based therapies for severe resistance infections in France. The company develops and commercializes red cell-based therapies for cancers and orphan diseases. It develops anti-infectious therapies based on the use of bacteriophages (phages) to treat infections caused by Escherichia coli (E.coli), Pseudomonas aeruginosa (P.aeruginosa), and Staphylococcus aureus (S.aureus). The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. The company was incorporated in 2004 and is headquartered in Lyon, France.
Show More
CEO
Mr. Thibaut du Fayet
Employees
68
Country
United States
ISIN
US29604W1080
WKN
000A3EV39
Listings
0 Comments
Share your thoughts
FAQs
What is Erytech Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Erytech Pharma stocks are traded under the ticker 2E4A.STU.
What is Erytech Pharma revenue for the last year?▼
Erytech Pharma revenue for the last year amounts to 0 EUR.
What is Erytech Pharma net income for the last year?▼
2E4A.STU net income for the last year is -23.49M EUR.
How many employees does Erytech Pharma have?▼
As of November 2, 2026, the company has 68 employees.
In which sector is Erytech Pharma located?▼
Erytech Pharma operates in the Other sector.
When did Erytech Pharma complete a stock split?▼
The last stock split for Erytech Pharma was on September 18, 2023 with a ratio of 1:10.
Where is Erytech Pharma headquartered?▼
Erytech Pharma is headquartered in Lyon, United States.